Olympus Corporation
Notice Regarding Issuance of Import Alerts by the FDA
The FDA-issued import alert restricts importation into the United States of certain products from the affected facilities. No additional impact on consolidated results for the fiscal year ending March 2027 is expected. Existing products maintain safety and effectiveness when used according to labeling; there is currently no impact on imports to other countries. The company will maintain transparency and outline its response policy.
Key Figures
- Affected facilities: Hinode (Olympus Medical Systems Corporation) / Shirakawa / Aomori
- Date of import alert publication: 2026-10-19
- Impact on consolidated results for FY ending March 2027: No additional impact expected
AI要約
Key points of the news
The FDA has published an import alert for certain Olympus Corporation products. The affected facilities are subsidiaries in Hinode, Shirakawa, and Aomori. Importation of the specified products into the United States will be restricted until further notice.
Impact and response
No additional impact on consolidated results for the fiscal year ending March 2027 is expected. For existing customers, safety and effectiveness will be ensured by adherence to product labeling. At this time, there is no impact on imports to other countries. The company intends to cooperate with transparency to resolve the issues noted by the FDA.
Olympus Corporation
Company overview · Stock price · Financial data · All IR
